---
schema_version: "secwatch.filing_event.v1"
accession: "0001159036-23-000006"
form_type: "8-K"
ticker: "HALO"
cik: "0001159036"
company_name: "HALOZYME THERAPEUTICS, INC."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-19T23:50:17.302296+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Halozyme elects Barbara Duncan to Board of Directors; Audit Committee assignment

## Summary
- Barbara Duncan elected to Board on Feb 3, 2023, with term expiring at 2024 annual meeting.
- Initially assigned to serve on the Audit Committee.
- Compensation follows non-employee director program; no related-party transactions disclosed.

## SEC filing metadata
- accession: 0001159036-23-000006
- form_type: 8-K
- ticker: HALO
- cik: 0001159036
- company_name: HALOZYME THERAPEUTICS, INC.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/0001159036-23-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/halo-20230203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001159036-23-000006
- JSON: https://secwatch.observer/filing/0001159036-23-000006.json
- Plain text: https://secwatch.observer/filing/0001159036-23-000006.txt

## Key facts
- Executive change
  Barbara Duncan was elected as Director at HALOZYME THERAPEUTICS, INC..
  - Action: elected
  - Role: Director
  source text: On February 3, 2023, Barbara Duncan was elected to the Board of Directors of Halozyme Therapeutics, Inc.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1159036/000115903623000006/0001159036-23-000006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.